Publications (8) Manuel Rodríguez López publications

2023

  1. Galician Experience with Avatrombopag: Galician Thrombosis and Hemostasis Group

    Blood, Vol. 142, Núm. Supplement 1, pp. 5446-5446

2022

  1. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products

    Thrombosis Research, Vol. 216, pp. 35-42

2021

  1. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  2. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

    Expert Opinion on Biological Therapy, Vol. 21, Núm. 9, pp. 1165-1171

  3. Management of acquired hemophilia A: results from the Spanish registry

    Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829

2020

  1. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain

    BMJ Case Reports, Vol. 13, Núm. 10

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

    Research and Practice in Thrombosis and Haemostasis, Vol. 3, Núm. 3, pp. 528-541